These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24289638)

  • 21. [Assessment of HER2 gene amplification in breast cancer: a comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization].
    Xu Y; Yang W; Yang F; Lu Y; Cai X; Zhou X
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):226-30. PubMed ID: 24915811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of fluorescence in situ hybridization (FISH) and dual-ISH (DISH) in the determination of HER2 status in breast cancer.
    Mansfield AS; Sukov WR; Eckel-Passow JE; Sakai Y; Walsh FJ; Lonzo M; Wiktor AE; Dogan A; Jenkins RB
    Am J Clin Pathol; 2013 Feb; 139(2):144-50. PubMed ID: 23355198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HER2 status in gastro-oesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH).
    Boers JE; Meeuwissen H; Methorst N
    Histopathology; 2011 Feb; 58(3):383-94. PubMed ID: 21323962
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer.
    Horii R; Matsuura M; Iwase T; Ito Y; Akiyama F
    Breast Cancer; 2014 Sep; 21(5):598-604. PubMed ID: 23307494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.
    García-Caballero T; Prieto O; Vázquez-Boquete A; Gude F; Viaño P; Otero M; Curiel T; Fernández-Rodríguez B; Parrado C; Fraga M; Antúnez JR
    Breast Cancer Res Treat; 2014 Jan; 143(1):81-9. PubMed ID: 24292870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH.
    Bartlett JM; Campbell FM; Ibrahim M; Wencyk P; Ellis I; Kay E; Connolly Y; O'Grady A; Di Palma S; Starczynski J; Morgan JM; Jasani B; Miller K
    Am J Clin Pathol; 2009 Oct; 132(4):514-20. PubMed ID: 19762528
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HER2 status determination using RNA-ISH--a rapid and simple technique showing high correlation with FISH and IHC in 141 cases of breast cancer.
    Alba J; Gutierrez J; Coupe VM; Fernández B; Vázquez-Boquete Á; Alba J; Forteza J; García-Caballero T
    Histol Histopathol; 2012 Aug; 27(8):1021-7. PubMed ID: 22763874
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Automated silver-enhanced in situ hybridization detection assay for human epidermal growth factor receptor 2 gene status determination in breast cancer].
    Ying JM; Guo L; Liu XY; Qiu T; Lü N
    Zhonghua Yi Xue Za Zhi; 2010 Jun; 90(24):1674-7. PubMed ID: 20979875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of HER2 Dual-Color and Fluorescence In Situ Hybridization in Breast Cancer:  A Cohort Study Emphasizing Equivocal Cases.
    Shao T; Wood M; Wing A; Hnatovska M; Mendes M; Brendan Mullen J; Chang MC
    Am J Clin Pathol; 2016 Sep; 146(3):339-45. PubMed ID: 27543979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
    Grin A; Brezden-Masley C; Bauer S; Streutker CJ
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.
    García-García E; Gómez-Martín C; Angulo B; Conde E; Suárez-Gauthier A; Adrados M; Perna C; Rodríguez-Peralto JL; Hidalgo M; López-Ríos F
    Histopathology; 2011 Jul; 59(1):8-17. PubMed ID: 21771023
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of fluorescence in-situ hybridisation with dual-colour in-situ hybridisation for assessment of HER2 gene amplification of breast cancer in Hong Kong.
    Tang SM; Soong IS; Luk MY; Suen DT; Hioe F; Man EP; Tsun OK; Khoo US
    Hong Kong Med J; 2016 Apr; 22(2):144-51. PubMed ID: 26823385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Dual-color silver-enhanced in-situ hybridization and fluorescence in-situ hybridization for determination of HER2 gene status in gastric carcinoma].
    Long XY; Bu H; Wei B; Liu XY; Chen M; Chen J; Liu JP
    Zhonghua Bing Li Xue Za Zhi; 2011 May; 40(5):300-3. PubMed ID: 21756822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chromogenic and Silver in Situ Hybridization for Identification of HER 2 Overexpression in Breast Cancer Patients: A Systematic Review and Meta-Analysis.
    Grazziotin LR; Dada BR; de la Rosa Jaimes C; Cheung WY; Marshall DA
    Appl Immunohistochem Mol Morphol; 2020 Jul; 28(6):411-421. PubMed ID: 31135445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens.
    García-Caballero T; Grabau D; Green AR; Gregory J; Schad A; Kohlwes E; Ellis IO; Watts S; Mollerup J
    Histopathology; 2010 Mar; 56(4):472-80. PubMed ID: 20459554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast carcinomas with low amplified/equivocal HER2 by Ish: potential supporting role of multiplex ligation-dependent probe amplification.
    Ercolani C; Marchiò C; Di Benedetto A; Fabi A; Perracchio L; Vici P; Sperati F; Buglioni S; Arena V; Pescarmona E; Sapino A; Terrenato I; Mottolese M
    J Exp Clin Cancer Res; 2017 Oct; 36(1):143. PubMed ID: 29029640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.